Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
INTI Inhibitor Therapeutics	$0.05 -2.1%	$0.05	$0.03 ▼ $0.10	$8.09M	-0.53	6,038 shs	4,000 shs
KZR Kezar Life Sciences	$4.44 +4.0%	$4.30	$3.62 ▼ $9.18	$32.46M	0.58	52,479 shs	46,562 shs
PVCT Provectus Biopharmaceuticals	$0.08 -1.6%	$0.08	$0.04 ▼ $0.15	$31.52M	0.79	165,538 shs	149,710 shs
RNTX Rein Therapeutics	$1.47 +1.4%	$1.85	$1.35 ▼ $4.40	$32.56M	1.3	29,357 shs	111,270 shs

12 Stocks Corporate Insiders are Abandoning

If a company's CEO, COO, and CFO were all selling shares of their stock, would you want to know? MarketBeat just compiled its list of the twelve stocks that corporate insiders are abandoning. Complete the form below to see which companies made the list.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
INTI Inhibitor Therapeutics	0.00%	+8.06%	+11.67%	-6.20%	-40.63%
KZR Kezar Life Sciences	0.00%	-1.77%	+6.47%	-9.02%	-26.00%
PVCT Provectus Biopharmaceuticals	0.00%	+0.13%	-11.87%	-25.00%	-40.52%
RNTX Rein Therapeutics	0.00%	-4.55%	-23.44%	-16.95%	+146,999,900.00%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
INTI Inhibitor Therapeutics	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
KZR Kezar Life Sciences	4.2798 of 5 stars	3.2	3.0	0.0	4.6	3.3	1.7	0.6
PVCT Provectus Biopharmaceuticals	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
RNTX Rein Therapeutics	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
INTI Inhibitor Therapeutics	0.00	N/A	N/A	N/A
KZR Kezar Life Sciences	2.33	Hold	$39.50	789.64% Upside
PVCT Provectus Biopharmaceuticals	0.00	N/A	N/A	N/A
RNTX Rein Therapeutics	0.00	N/A	N/A	N/A

Current Analyst Ratings Breakdown

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
INTI Inhibitor Therapeutics	N/A	N/A	N/A	N/A	$0.01 per share	N/A
KZR Kezar Life Sciences	$7M	4.64	N/A	N/A	$16.02 per share	0.28
PVCT Provectus Biopharmaceuticals	$620K	50.84	N/A	N/A	($0.01) per share	-7.50
RNTX Rein Therapeutics	N/A	N/A	$0.45 per share	3.28	$0.43 per share	N/A

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
INTI Inhibitor Therapeutics	-$3.34M	-$0.01	N/A	∞	N/A	N/A	-120.86%	-55.21%	8/4/2025 (Estimated)
KZR Kezar Life Sciences	-$83.74M	-$10.82	N/A	N/A	N/A	N/A	-61.15%	-50.27%	8/12/2025 (Estimated)
PVCT Provectus Biopharmaceuticals	-$4.76M	N/A	0.00	∞	N/A	-815.81%	N/A	-644.80%	8/11/2025 (Estimated)
RNTX Rein Therapeutics	-$62.88M	-$2.86	N/A	N/A	N/A	N/A	-86.07%	-31.11%	N/A

Latest INTI, RNTX, PVCT, and KZR Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
5/15/2025	Q1 2025	RNTX Rein Therapeutics	-$0.21	-$0.25	-$0.04	-$0.25	N/A	N/A
5/13/2025	Q1 2025	KZR Kezar Life Sciences	-$2.56	-$2.27	+$0.29	-$2.27	N/A	N/A
4/7/2025	Q4 2024	RNTX Rein Therapeutics	N/A	-$0.26	N/A	-$1.89	N/A	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
INTI Inhibitor Therapeutics	N/A	N/A	N/A	N/A	N/A
KZR Kezar Life Sciences	N/A	N/A	N/A	N/A	N/A
PVCT Provectus Biopharmaceuticals	N/A	N/A	N/A	N/A	N/A
RNTX Rein Therapeutics	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
INTI Inhibitor Therapeutics	N/A	46.68	46.68
KZR Kezar Life Sciences	0.04	7.09	7.09
PVCT Provectus Biopharmaceuticals	N/A	0.11	0.11
RNTX Rein Therapeutics	N/A	1.39	1.39

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
INTI Inhibitor Therapeutics	N/A
KZR Kezar Life Sciences	67.90%
PVCT Provectus Biopharmaceuticals	0.05%
RNTX Rein Therapeutics	90.89%

Insider Ownership

Company	Insider Ownership
INTI Inhibitor Therapeutics	4.60%
KZR Kezar Life Sciences	9.30%
PVCT Provectus Biopharmaceuticals	12.80%
RNTX Rein Therapeutics	5.10%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
INTI Inhibitor Therapeutics	1	172.57 million	164.64 million	Not Optionable
KZR Kezar Life Sciences	60	7.31 million	6.63 million	Not Optionable
PVCT Provectus Biopharmaceuticals	4	420.28 million	366.48 million	Not Optionable
RNTX Rein Therapeutics	9	22.15 million	21.02 million	N/A

INTI, RNTX, PVCT, and KZR Headlines

Recent News About These Companies

RNTX - Rein Therapeutics Inc Dividends - Morningstar

June 26, 2025 | morningstar.comM

Rein Therapeutics Announces Adjournment of Annual Meeting of Stockholders

June 24, 2025 | prnewswire.com

US FDA puts on hold Rein Therapeutics' lung disease drug trial

June 12, 2025 | reuters.com

RNTX Rein Therapeutics Inc.

June 1, 2025 | seekingalpha.com

Rein Therapeutics, Inc.: Rein Therapeutics Announces First Patient Dosed in RENEW Phase 2 Trial of LTI-03 in Patients with IPF

May 27, 2025 | finanznachrichten.de

Rein Therapeutics Announces First Patient Dosed in RENEW Phase 2 Trial of LTI-03 in Patients with IPF

May 27, 2025 | prnewswire.com

Rein Therapeutics Presents Two Posters at the American Thoracic Society 2025 International Conference

May 19, 2025 | prnewswire.com

Rein Therapeutics, Inc.: Rein Therapeutics Reports First Quarter 2025 Financial Results and Provides Business Update

May 16, 2025 | finanznachrichten.de

Rein Therapeutics Reports First Quarter 2025 Financial Results and Provides Business Update

May 15, 2025 | prnewswire.com

Rein Therapeutics begins trial for idiopathic pulmonary fibrosis treatment

May 13, 2025 | msn.com

Rein Therapeutics, Inc.: Rein Therapeutics Announces Initiation of RENEW Phase 2 Trial of LTI-03 in Patients with IPF

May 12, 2025 | finanznachrichten.de

Rein Therapeutics Announces Initiation of RENEW Phase 2 Trial of LTI-03 in Patients with IPF

May 12, 2025 | prnewswire.com

Rein Therapeutics to integrate Qureight’s platform in trial of IPF treatment

May 2, 2025 | msn.com

Rein Therapeutics and Qureight Ltd Announce Planned Integration of Deep-Learning Platform for Phase 2 Trial of LTI-03 in Patients with IPF

May 1, 2025 | prnewswire.com

Rein Therapeutics to Present at The Citizens Life Sciences Conference 2025

April 30, 2025 | prnewswire.com

Rein Therapeutics Announces Abstract Accepted for Presentation at the American Thoracic Society 2025 International Conference

April 28, 2025 | prnewswire.com

Rein Therapeutics Granted Two Patents Covering the Novel Formulation and Administration Methods of Dry Powder LTI-03 for the Treatment of Respiratory Diseases

April 23, 2025 | prnewswire.com

Rein Therapeutics reports IPF and PASC-F treatment progress

April 17, 2025 | uk.investing.com

Rein Therapeutics’ LTI-2355 peptide shows therapuetic potential in study

April 16, 2025 | markets.businessinsider.com

Rein Therapeutics Announces a Publication in Biomedicines on the Immunomodulatory and Anti-fibrotic Properties of a Caveolin-1-Related Peptide in IPF and PASC-F

April 15, 2025 | prnewswire.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All

IPO Momentum Returns: 3 Stocks Rising After CoreWeave’s Surge
By Dan Schmidt | June 20, 2025
View IPO Momentum Returns: 3 Stocks Rising After CoreWeave’s Surge
BigBear.ai Poised to Benefit as Palantir Dominates AI Defense
By Gabriel Osorio-Mazilli | June 23, 2025
View BigBear.ai Poised to Benefit as Palantir Dominates AI Defense
Intel's Turnaround Strategy Shifts From Planning to Attack Mode
By Jeffrey Neal Johnson | June 20, 2025
View Intel's Turnaround Strategy Shifts From Planning to Attack Mode
3 Semiconductor Stocks Poised to Surge on AI Spending
By Chris Markoch | June 25, 2025
View 3 Semiconductor Stocks Poised to Surge on AI Spending
Why Dollar General May Be Retail’s Most Undervalued Rebound
By Jeffrey Neal Johnson | June 2, 2025
View Why Dollar General May Be Retail’s Most Undervalued Rebound

INTI, RNTX, PVCT, and KZR Company Descriptions

Inhibitor Therapeutics OTCMKTS:INTI

$0.05 0.00 (-2.09%)

As of 06/27/2025 03:16 PM Eastern

Inhibitor Therapeutics, Inc., a pharmaceutical development company, develops and commercializes therapeutics for patients with certain cancers and non-cancerous proliferation disorders in the United States. The company engages in the development of therapies for prostate and lung cancer utilizing itraconazole; and conducted a positive Phase 2b clinical trial of SUBA-Itraconazole for the treatment of basal cell carcinoma nevus syndrome. It has license agreement with Johns Hopkins University. The company was formerly known as HedgePath Pharmaceuticals, Inc. and changed its name to Inhibitor Therapeutics, Inc. in August 2019. Inhibitor Therapeutics, Inc. was founded in 1992 and is based in Tampa, Florida. Inhibitor Therapeutics, Inc operates as a subsidiary of Mayne Pharma Ventures Pty Ltd.

Kezar Life Sciences NASDAQ:KZR

$4.44 +0.17 (+3.98%)

Closing price 06/27/2025 04:00 PM Eastern

Extended Trading

$4.28 -0.16 (-3.60%)

As of 04:05 AM Eastern

Kezar Life Sciences, Inc., a clinical-stage biotechnology company, engages in the discovery and development of novel small molecule therapeutics to treat unmet needs in immune-mediated diseases and cancer in the United States. The company's lead product candidate is zetomipzomib (KZR-616), a selective immunoproteasome inhibitor that is in Phase 2b clinical trials for various indications, including lupus nephritis, dermatomyositis, and polymyositis; Phase 1b clinical trials in systemic lupus erythematosus; and completed Phase 2a clinical trials in lupus nephritis. Its preclinical products include KZR-261, a novel first-in-class protein secretion inhibitor for the treatment of tumors resistant to traditional chemotherapeutics. Kezar Life Sciences, Inc. was incorporated in 2015 and is headquartered in South San Francisco, California.

Provectus Biopharmaceuticals OTCMKTS:PVCT

$0.08 0.00 (-1.57%)

As of 06/27/2025 03:55 PM Eastern

Provectus Biopharmaceuticals, Inc., a clinical-stage biotechnology company, engages in developing immunotherapy medicines based on halogenated xanthenes in the United States. The company's lead molecule is rose bengal sodium (RBS). Its clinical development programs include PV-10 for the treatment of stage III and IV melanoma and different types of liver cancers; PH-10 for the treatment of psoriasis and atopic dermatitis, and skin inflammation; and PV-305 for the treatment of infectious keratitis. It is also developing oral formulations for adult solid tumor cancers, as well as refractory and relapsed pediatric, and other blood cancers comprising leukemias; PV-10 for the treatment of relapsed and refractory pediatric solid tumor cancers; and other formulations for the treatment of cutaneous canine cancers and healing of full-thickness cutaneous wounds. In addition, the company develops oral and intranasal formulations for the treatment of severe acute respiratory syndrome coronavirus 2; gram-positive and gram-negative bacterial infections; oral bacterial infections; and fungal infections, as well as vertebrate development, wound healing, and tissue regrowth. It has collaboration agreement with Bascom Palmer Eye Institute; and University of Miami. The company was formerly known as Provectus Pharmaceuticals, Inc. and changed its name to Provectus Biopharmaceuticals, Inc. in December 2013. Provectus Biopharmaceuticals, Inc. was founded in 2002 and is based in Knoxville, Tennessee.

Rein Therapeutics NASDAQ:RNTX

$1.47 +0.02 (+1.38%)

As of 06/27/2025 04:00 PM Eastern

Rein Therapeutics, Inc. is a clinical stage biopharmaceutical company, which engages in the development and commercialization of a novel class of therapeutics for the treatment of cancer and other diseases. It focuses on its lead product candidate, ALRN-6924, which is a cell-permeating peptide that disrupts the interaction of p53 suppressors MDM2 and MDMX with tumor suppressor p53 to reactivate tumor suppression in non-mutant, or wild-type, p53 cancers. The company was founded by Gregory L. Verdine, Rosana Kapeller, Huw M. Nash, Joseph A. Yanchik III, and Loren David Walensky on August 6, 2001 and is headquartered in Austin, TX.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time